Taris Biomedical LLC
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer (NCT03518320) | Taris Biomedical LLC | 2019-01-02 |
| Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury (NCT03168828) | Taris Biomedical LLC | 2017-04-24 |
| Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder (NCT03109379) | Taris Biomedical LLC | 2017-04-04 |
| Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer (NCT02722538) | Taris Biomedical LLC | 2016-05-31 |
| Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer (NCT02720367) | Taris Biomedical LLC | 2016-01-01 |
Track Taris Biomedical LLC automatically
Every clearance here is in the API, with alerts when new ones post.